Nasal spray to treat Covid-19 enters phase 2 trials

October 07, 2021

Nasal spray to treat Covid-19 enters phase 2 trials

One of our Stoic VC investee companies, ENA Respiratory, that offers huge potential in how we might deal with the pandemic globally.

A nasal spray offering users protection from Covid-19 could soon be employed as another line of defence against the virus, as encouraging results from a preliminary trial of the solution trigger a second phase of studies.

The revolutionary spray could provide almost immediate protection against coronavirus and influenza by activating natural immunity in the nose and throat, where respiratory viruses enter the body. The treatment, which uses the compound INNA-051, is being researched by Hunter Medical Research Institute and University of Newcastle respiratory researchers, who are developing the treatment for Australian biotech company Ena Respiratory.

“We discovered that INNA-051 is very effective at priming the airways to more rapidly and effectively respond to a viral infection,” associate professor Nathan Bartlett, from the University of Newcastle and head of HMRI’s Viral Immunology and Respiratory Disease Group, said. “HMRI’s proof of concept data was instrumental in ensuring the treatment was ideally placed to be tested against the virus that causes Covid-19.”

Professor Bartlett began work with Ena Respiratory prior to the pandemic to target the primary entry site for viral respiratory infections, including flu and common colds.

Later pre-clinical studies found the treatment was also effective in treating Covid-19.

INNA-051 would work to complement a vaccine, particularly where inoculation is likely to be less effective such as the elderly, patients with chronic lung disease and the immunocompromised.

“As we continue to combat current and emerging Covid-19 variants, there is a significant need for convenient therapies that boost protection in at-risk populations,” Ena Respiratory chief Christophe Demaison said. “By stimulating the innate immune response, we hope to create an extra line of defence against Covid-19 and other respiratory viral infections.”

The company is pushing ahead with phase-two trials across several countries to begin in January.

https://www.theaustralian.com.au/science/nasal-spray-to-treat-covid19-enters-phase-2-trials/news-story/a09cf897e316559f5ddb20c4b18ccb3d



Also in News

REVEAL | Mogo Zoo’s cub finally has a name voted by you!
REVEAL | Mogo Zoo’s cub finally has a name voted by you!

May 06, 2022

Earlier this week Mogo Zoo asked the 2GB listeners to help name their beautiful new lion cub.The poll was put out earlier this week and we have a winner!
Private healthcare operators rise to the challenge of Australia's growing and ageing population
Private healthcare operators rise to the challenge of Australia's growing and ageing population

May 06, 2022

Private healthcare operators rise to the challenge of Australia's growing and ageing population. Stresses on the public healthcare system are resulting in growing demand by private healthcare operators for high quality healthcare real estate.
Auror officially launches in the United Kingdom
Auror officially launches in the United Kingdom

May 06, 2022

Auror is officially launching their retail crime prevention platform into the UK market at Retail Risk London on 19 May 2022.